MBX Biosciences (MBX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MBX Biosciences (MBX) trades at $57.70 with AI Score 77/100 (Grade A). MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. Market cap: $1.94B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026MBX stock analysis for 2026: Analysts have set a consensus price target of $62.80 for MBX Biosciences, suggesting 8.8% upside from the current price of $57.70. The AI MoonshotScore is 77/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MBX: 1/1 perspectives are bullish.
How is this calculated? →MBX Biosciences (MBX) Healthcare & Pipeline Overview
MBX Biosciences is a clinical-stage biopharmaceutical company specializing in precision peptide therapies targeting endocrine and metabolic disorders. Their lead candidate, MBX 2109, is in Phase 2 trials for chronic hypoparathyroidism, positioning MBX as a potential innovator in hormone replacement therapies and related metabolic conditions, within the competitive biotechnology landscape.
What Is the Investment Thesis for MBX?
MBX Biosciences presents a notable research candidate due to its focus on precision peptide therapies for endocrine and metabolic disorders. The lead candidate, MBX 2109, addresses a critical need in chronic hypoparathyroidism, a market with limited effective treatments. Positive Phase 2 trial results could significantly increase the company's valuation. Furthermore, the development of MBX 1416 for post-bariatric hypoglycemia and MBX 4291 for obesity expands the company's potential market reach. Key risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's success hinges on the clinical validation and commercialization of its pipeline assets.
Based on FMP financials and quantitative analysis
MBX Key Highlights
- MBX 2109, the lead product candidate, is in Phase 2 clinical trials targeting chronic hypoparathyroidism, a market with significant unmet needs.
- MBX 1416, a long-acting GLP-1 receptor antagonist, is in Phase 1 clinical trials for post-bariatric hypoglycemia, expanding the company's therapeutic focus.
- MBX 4291, a lead obesity product candidate, is in investigational new drug-enabling studies, addressing the growing obesity market.
- The company was founded in 2018 and has a focused pipeline of precision peptide therapies.
- MBX Biosciences has a market capitalization of $1.94B, reflecting investor confidence in its pipeline and technology.
Who Are MBX's Competitors?
MBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ERAS Erasca, Inc. | $18.59 | +0.64% | $5.78B | 71 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| ABCL AbCellera Biologics Inc. | $7.87 | -2.96% | $2.40B | 76 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| KRRO Korro Bio, Inc. | $14.08 | +0.57% | $140.14M | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBX's Key Strengths?
- Focused pipeline of precision peptide therapies
- Lead candidate in Phase 2 clinical trials
- Experienced management team
- Strong intellectual property position
What Are MBX's Weaknesses?
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
What Could Drive MBX Stock Higher?
- Phase 2 clinical trial results for MBX 2109 in chronic hypoparathyroidism.
- Phase 1 clinical trial results for MBX 1416 in post-bariatric hypoglycemia.
- Investigational new drug-enabling studies for MBX 4291 in obesity.
- Potential strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for MBX?
- Negative return on equity (-24.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for MBX 2109, MBX 1416, or MBX 4291.
- Regulatory hurdles in obtaining approval for its drug candidates.
- Competition from established pharmaceutical companies with greater resources.
- Patent challenges to its intellectual property.
- Dependence on raising additional capital to fund research and development.
What Are the Growth Opportunities for MBX?
- Growth opportunity 1: Successful completion of Phase 2 clinical trials for MBX 2109 in chronic hypoparathyroidism represents a significant growth catalyst. Positive results could lead to accelerated regulatory approval and commercialization, capturing a substantial share of the hormone replacement therapy market. The global market for parathyroid hormone replacement therapy is projected to reach $1.5 billion by 2028, offering a substantial revenue opportunity for MBX Biosciences. This is expected to occur within the next 2-3 years.
- Growth opportunity 2: Advancement of MBX 1416 into later-stage clinical trials for post-bariatric hypoglycemia offers another growth avenue. This therapy addresses a specific complication of bariatric surgery, a growing market driven by increasing obesity rates. The market for post-bariatric hypoglycemia treatments is estimated at $500 million annually, providing a niche but valuable opportunity for MBX Biosciences. This is expected to occur within the next 3-4 years.
- Growth opportunity 3: The development of MBX 4291 as a long-acting GLP-1 and GIP receptor co-agonist for obesity represents a major growth opportunity. The obesity market is one of the largest and fastest-growing in the pharmaceutical industry, driven by increasing prevalence and awareness. The global obesity market is projected to exceed $40 billion by 2030, offering significant potential for MBX Biosciences. This is expected to occur within the next 4-5 years.
- Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of MBX Biosciences' pipeline assets. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. Such partnerships could unlock significant value and drive revenue growth. These partnerships are expected to materialize over the next 2-3 years.
- Growth opportunity 5: Expansion of the pipeline through the discovery and development of additional precision peptide therapies for other endocrine and metabolic disorders represents a long-term growth opportunity. By leveraging its expertise and technology platform, MBX Biosciences can create a diversified portfolio of drug candidates, mitigating risk and maximizing its potential for success. This is an ongoing effort with new candidates entering the pipeline every 1-2 years.
What Opportunities Does MBX Have?
- Successful commercialization of MBX 2109
- Expansion of pipeline into other endocrine and metabolic disorders
- Strategic partnerships with larger pharmaceutical companies
- Growing market for obesity and diabetes treatments
What Threats Does MBX Face?
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
What Are MBX's Competitive Advantages?
- Proprietary peptide technology platform
- Strong intellectual property protection for its drug candidates
- Clinical trial data demonstrating efficacy and safety
- Expertise in endocrine and metabolic disorders
What Does MBX Do?
MBX Biosciences, Inc., founded in 2018 and based in Carmel, Indiana, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision peptide therapies. The company focuses on addressing endocrine and metabolic disorders with innovative drug candidates. Their lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently undergoing Phase 2 clinical trials. This therapy is designed as a long-acting hormone replacement for individuals suffering from chronic hypoparathyroidism, a condition characterized by insufficient parathyroid hormone production. In addition to MBX 2109, MBX Biosciences is developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist. This candidate is in Phase 1 clinical trials and targets post-bariatric hypoglycemia, a complication arising from bariatric surgery. Furthermore, the company's pipeline includes MBX 4291, a lead obesity product candidate in investigational new drug-enabling studies. MBX 4291 is designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug, aimed at treating obesity and related co-morbidities. MBX Biosciences is committed to advancing novel peptide therapies to improve patient outcomes in areas with significant unmet medical needs.
What Products and Services Does MBX Offer?
- Develop precision peptide therapies for endocrine disorders
- Focus on treatments for metabolic disorders
- Develop MBX 2109, a parathyroid hormone peptide prodrug for chronic hypoparathyroidism
- Develop MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia
- Develop MBX 4291, a GLP-1 and GIP receptor co-agonist for obesity
- Conduct Phase 1 and Phase 2 clinical trials
- Pursue investigational new drug-enabling studies
How Does MBX Make Money?
- Discover and develop novel peptide therapeutics.
- Conduct clinical trials to evaluate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved therapies directly or through partnerships.
What Industry Does MBX Operate In?
MBX Biosciences operates within the biotechnology industry, which is characterized by intense research and development, high regulatory scrutiny, and significant growth potential. The market for endocrine and metabolic disorder treatments is substantial, driven by increasing prevalence of conditions like diabetes, obesity, and hypoparathyroidism. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. MBX Biosciences aims to differentiate itself through precision peptide therapies, offering potentially more targeted and effective treatments. The biotechnology industry is projected to continue growing, fueled by advancements in genomics, proteomics, and personalized medicine.
Who Are MBX's Key Customers?
- Patients with endocrine disorders like hypoparathyroidism
- Patients with metabolic disorders like post-bariatric hypoglycemia and obesity
- Healthcare providers who prescribe and administer these therapies
- Hospitals and clinics that treat these conditions
How MBX Biosciences Is Valued
MBX Biosciences carries a market capitalization of $1.94B, placing it in the small-cap category. Relative to its peer group, MBX's quantitative score of 77/100 is roughly in line with the peer average of 76/100.
Company Profile
MBX Biosciences operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carmel, US. The company is led by CEO Peter Kent Hawryluk. MBX has traded publicly since 2000.
ROE -25%Key Financial Metrics
Return on equity for MBX Biosciences stands at -24.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -19.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 30.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
MBX Biosciences's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 77.71 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project MBX Biosciences revenue of about $0 for fiscal 2026, with EPS near $-2.81.
MBX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MBX's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative research developments that could lead to breakthroughs in treatment.
- Analysts are noting the growing interest in biotech, especially in areas MBX is exploring, which could attract more investors and partnerships.
- Recent collaborations with reputable institutions have enhanced MBX's credibility and visibility in the market.
Bear Case
- Despite positive sentiment, there are concerns about the competitive landscape in biotech, where many companies are vying for attention and funding.
- Some investors are cautious due to the historically high volatility in biotech stocks, which can lead to unpredictable price movements.
- Recent market trends indicate a pullback in risk appetite, particularly for small-cap biotech firms, which could affect MBX's stock performance.
- Community discussions also reflect skepticism about the timelines for product development, with some questioning the feasibility of meeting projected milestones.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MBX Latest News
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Jun 12, 2026
-
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga · Jun 12, 2026
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
-
Earnings Scheduled For February 12, 2026
benzinga · Feb 12, 2026
MBX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MBX.
Price Targets
Consensus target: $62.80
MBX MoonshotScore
What does this score mean?
The MoonshotScore rates MBX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Earnings Scheduled For May 14, 2026
Earnings Scheduled For February 12, 2026
Leadership: Peter Kent Hawryluk
CEO
Peter Kent Hawryluk serves as the CEO of MBX Biosciences, bringing extensive experience in the biopharmaceutical industry. His career spans various leadership roles in both established and emerging companies, with a focus on drug development and commercialization. Prior to joining MBX Biosciences, Peter held key positions at several biotechnology firms, where he oversaw clinical operations, regulatory affairs, and business development. He holds an advanced degree in a scientific field and has a proven track record of successfully navigating the complexities of the pharmaceutical industry.
Track Record: Under Peter's leadership, MBX Biosciences has advanced its lead product candidate, MBX 2109, into Phase 2 clinical trials. He has also overseen the expansion of the company's pipeline with the addition of MBX 1416 and MBX 4291. Peter has successfully raised capital to fund the company's research and development efforts and has built a strong team of scientists and executives.
What Investors Ask About MBX Biosciences (MBX) — Healthcare
What does MBX Biosciences, Inc. Common Stock do?
MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. Their primary focus is on creating innovative treatments for conditions like chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company's lead product candidate, MBX 2109, is currently in Phase 2 clinical trials for chronic hypoparathyroidism. MBX Biosciences aims to address unmet medical needs by developing targeted and effective peptide-based therapeutics.
What do analysts say about MBX stock?
Analyst coverage of MBX Biosciences reflects optimism regarding its pipeline and technology platform. Key valuation metrics include potential peak sales for its lead product candidates and the overall market opportunity in endocrine and metabolic disorders. Growth considerations center on the successful completion of clinical trials and regulatory approval timelines. Analyst consensus generally acknowledges the inherent risks associated with clinical-stage biotech companies but recognizes the potential for significant upside if MBX Biosciences achieves its development milestones.
What are the main risks for MBX?
The primary risks for MBX Biosciences include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. Clinical trial outcomes are inherently uncertain, and negative results could significantly impact the company's valuation. Securing regulatory approval from agencies like the FDA is a complex and lengthy process. MBX Biosciences also faces competition from established companies with greater resources and more advanced product pipelines. Additionally, the company is dependent on raising additional capital to fund its research and development efforts.
How does MBX Biosciences, Inc. Common Stock navigate regulatory approval processes?
MBX Biosciences navigates regulatory approval processes by adhering to strict guidelines set by regulatory bodies such as the FDA. This involves comprehensive preclinical studies, well-designed clinical trials, and detailed documentation of safety and efficacy data. The company maintains ongoing communication with regulatory agencies to address any concerns and ensure compliance with all applicable regulations. MBX Biosciences also invests in regulatory expertise to effectively manage the approval process and minimize potential delays.
How does MBX Biosciences, Inc. Common Stock manage patent expiration risks?
MBX Biosciences manages patent expiration risks through a multi-faceted approach. This includes actively seeking patent protection for its novel peptide therapies and formulations, as well as pursuing strategies to extend patent life through formulation enhancements and new indications. The company also monitors the competitive landscape for potential patent infringements and takes appropriate legal action to protect its intellectual property. Furthermore, MBX Biosciences invests in research and development to create new and innovative therapies that are not subject to existing patent limitations.
What are the key factors to evaluate for MBX?
MBX Biosciences (MBX) holds an AI score of 77/100 (high). Analysts target $62.80 (+9%). Not financial advice.
How frequently does MBX data refresh on this page?
MBX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MBX's recent stock price performance?
MBX Biosciences (MBX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused pipeline of precision peptide therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Analyst opinions may vary.